Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 195NIH 84INDUSTRY 26NETWORK 15FED 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Prostatic Neoplasms 46Neoplasms 36Colorectal Neoplasms 36Lung Neoplasms 21Breast Neoplasms 13Colonic Polyps 11Colonic Neoplasms 11Rare Diseases 9Carcinoma, Non-Small-Cell Lung 9Carcinoma, Hepatocellular 7Pulmonary Disease, Chronic Obstructive 6Neoplasm Metastasis 6Heart Failure 6Ovarian Neoplasms 5Motor Activity 5Liver Neoplasms 5Head and Neck Neoplasms 5Fibrosis 5Carcinoma, Squamous Cell 5Barrett Esophagus 5Adenoma 5Urinary Bladder Neoplasms 4Neoplasms by Site 4Mental Disorders 4Lymphoma 4Lung Diseases 4Leukemia 4Esophageal Neoplasms 4Adenocarcinoma Of Esophagus 4Urinary Incontinence 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FED × Interventional × Sezary Syndrome × Clear all
NCT00099593 2015-03-25

Immunization Against Tumor Cells in Sezary Syndrome

FDA Office of Orphan Products Development

Phase 2 Completed
17 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡